JP2005525089A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525089A5
JP2005525089A5 JP2003552801A JP2003552801A JP2005525089A5 JP 2005525089 A5 JP2005525089 A5 JP 2005525089A5 JP 2003552801 A JP2003552801 A JP 2003552801A JP 2003552801 A JP2003552801 A JP 2003552801A JP 2005525089 A5 JP2005525089 A5 JP 2005525089A5
Authority
JP
Japan
Prior art keywords
producing
pharmaceutically acceptable
pharmaceutical composition
acceptable carrier
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003552801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/014325 external-priority patent/WO2003051921A1/en
Publication of JP2005525089A publication Critical patent/JP2005525089A/ja
Publication of JP2005525089A5 publication Critical patent/JP2005525089A5/ja
Pending legal-status Critical Current

Links

JP2003552801A 2001-12-17 2002-12-16 ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 Pending JP2005525089A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000761 2001-12-17
PCT/EP2002/014325 WO2003051921A1 (en) 2001-12-17 2002-12-16 Chemokine mutants acting as chemokine antagonists

Publications (2)

Publication Number Publication Date
JP2005525089A JP2005525089A (ja) 2005-08-25
JP2005525089A5 true JP2005525089A5 (enExample) 2006-01-05

Family

ID=8176112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552801A Pending JP2005525089A (ja) 2001-12-17 2002-12-16 ケモカイン・アンタゴニストとして作用するケモカイン突然変異体

Country Status (10)

Country Link
US (1) US7553483B2 (enExample)
EP (1) EP1458756B1 (enExample)
JP (1) JP2005525089A (enExample)
AT (1) ATE421974T1 (enExample)
AU (1) AU2002358144B2 (enExample)
CA (1) CA2468790A1 (enExample)
DE (1) DE60231057D1 (enExample)
ES (1) ES2320743T3 (enExample)
IL (1) IL162600A0 (enExample)
WO (1) WO2003051921A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507008A1 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
ATE322506T1 (de) * 2004-01-19 2006-04-15 Ares Trading Sa Verfahren zur reinigung von in bakterien exprimierten proteinen
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2380975A1 (de) * 2010-04-22 2011-10-26 Scil Proteins GmbH Verfahren zur Herstellung von rekombinantem Thrombin
US9352000B2 (en) * 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
EP3307330B1 (en) * 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
WO2017077062A1 (en) * 2015-11-05 2017-05-11 Ludwig-Maximilians-Universität München A peptide derived from human neutrophile peptide 1
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
WO2023057589A1 (en) 2021-10-06 2023-04-13 Virothera Ltd Novel immune regulator

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679436B2 (en) * 1991-12-23 1997-07-03 British Bio-Technology Limited Stem cell inhibiting proteins
HU221089B1 (en) * 1994-12-08 2002-08-28 Glaxo Group Ltd Rantes peptide derivates with antagonistic effect and uses thereof
JP2001506492A (ja) * 1996-12-05 2001-05-22 ヒューマン ゲノム サイエンシズ インク. ヒトケモカインβ−13
AU5137698A (en) 1996-12-05 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Novel dna, novel protein, and novel antibody
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
CA2316447C (en) 1997-12-23 2009-07-28 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
JPH11243960A (ja) * 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトcc型ケモカインエオタキシン3
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
JP2006516528A5 (enExample)
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
JP2005509846A5 (enExample)
JP2006503588A5 (enExample)
JP2004532810A5 (enExample)
JP2004529078A5 (enExample)
JP2005501039A (ja) 可変放出割合を持つ薬剤制御放出システム
JP2004525194A5 (enExample)
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
JP2005518413A5 (enExample)
JP2005515404A5 (enExample)
JP2006006329A5 (enExample)
JP2006502129A5 (enExample)
JP2006517944A5 (enExample)
JP2005538045A5 (enExample)
JP2007501782A5 (enExample)
JP2003213455A5 (enExample)
JP2004529205A5 (enExample)
JP2006505391A5 (enExample)
JP2004517961A5 (enExample)
JPH10237071A5 (enExample)
JP2006527741A5 (enExample)
JP2002277470A5 (enExample)
JP2006501334A5 (enExample)
JP2006500360A5 (enExample)